Expert Video - What is the importance of combination therapies for BRAF?
Dr. Robert Winn, an expert on cancer mutations, explains the importance of combination therapies for BRAF mutations in non-small-cell lung cancer. BRAF mutations are targeted with combination, or two-drug, therapy. He explains how using more than one drug can be more effective at treating non-small-cell lung cancer and how this approach applies to other mutations as well.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
This educational activity has been developed by
A Breath of Hope Lung Foundation and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Foundation Inc., Bristol-Myers Squibb Grants and Giving, Foundation Medicine, Genentech, Merck Sharp & Dohme LLC , Neogenomics, Novartis, and Pfizer.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.